Oncternal Financial Statements From 2010 to 2024

Stocks . USA . 
Stock . Oncternal Therapeutics
ONCT Stock  USD 0.71  0.43  37.72%   
Oncternal Therapeutics financial statements provide useful quarterly and yearly information to potential Oncternal Therapeutics investors about the company's current and past financial position, as well as its overall management performance and changes in financial position over time. Historical trend examination of various income statement and balance sheet accounts found on Oncternal Therapeutics financial statements helps investors assess Oncternal Therapeutics' valuation, profitability, and current liquidity needs. Key fundamental drivers impacting Oncternal Therapeutics' valuation are summarized below:
Gross Profit
-31.5 M
Market Capitalization
3.4 M
Enterprise Value Revenue
0.8526
Revenue
2.2 M
Earnings Share
(11.69)
There are currently one hundred twenty trending fundamental ratios for Oncternal Therapeutics that can be evaluated and compared over time across competitors. All traders should check out Oncternal Therapeutics' recent fundamentals against the performance from 2010 to 2024 and make sure the trends continue to evolve in the right direction. Market Cap is likely to drop to about 34.4 M in 2024. Enterprise Value is likely to drop to about 27.5 M in 2024

Oncternal Therapeutics Total Revenue

745,750

Check Oncternal Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Oncternal Therapeutics' main balance sheet or income statement drivers, such as Depreciation And Amortization of 43.8 M, Interest Expense of 847.7 K or Other Operating Expenses of 36.2 M, as well as many indicators such as Price To Sales Ratio of 38.14, Dividend Yield of 1.0E-4 or PTB Ratio of 1.0. Oncternal financial statements analysis is a perfect complement when working with Oncternal Therapeutics Valuation or Volatility modules.
  
Check out the analysis of Oncternal Therapeutics Correlation against competitors.
For more information on how to buy Oncternal Stock please use our How to Invest in Oncternal Therapeutics guide.

Oncternal Therapeutics Balance Sheet

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Total Assets61.3 M36.7 M49.3 M
Slightly volatile
Cash6.4 M6.7 M32.7 M
Pretty Stable
Other Assets1.7 M1.1 M711.8 K
Slightly volatile
Cash And Short Term Investments55.2 M34.3 M46.7 M
Slightly volatile
Common Stock Shares Outstanding3.1 M2.9 M1.8 M
Slightly volatile
Other Stockholder Equity321.4 M227.8 M364.8 M
Pretty Stable
Total Liabilities6.3 M6.7 M9.5 M
Pretty Stable
Total Current Assets58.6 M36.1 M48.5 M
Slightly volatile
Other Current Liabilities7.3 M3.9 M7.7 M
Pretty Stable
Total Current Liabilities4.9 M5.2 M9.2 M
Pretty Stable
Property Plant And Equipment Net245.1 K258 K257.3 K
Slightly volatile
Accounts Payable1.6 M1.1 M1.5 M
Slightly volatile
Non Current Assets Total636.5 K670 K671.6 K
Very volatile
Common Stock Total Equity50.6 K65.5 K55.6 K
Very volatile
Other Current Assets1.6 M1.2 M1.6 M
Slightly volatile
Property Plant And Equipment Gross245.1 K258 K257.3 K
Slightly volatile
Common Stock2.9 K3 K47.7 K
Slightly volatile
Short and Long Term Debt Total333.9 K318 K148.1 K
Slightly volatile
Intangible Assets80.4 K84.6 K602.7 K
Slightly volatile
Net Receivables600.4 K632 K736.6 K
Very volatile
Short Term Debt164.3 K173 K562.4 K
Slightly volatile
Capital Surpluse340.7 M197.3 M393.3 M
Slightly volatile
Non Current Liabilities Other25.6 K27 K114.8 K
Slightly volatile
Property Plant Equipment152.8 K78.3 K241.3 K
Slightly volatile
Net Invested Capital58.3 M30.1 M46.5 M
Slightly volatile
Net Working Capital57.8 M30.9 M46.1 M
Slightly volatile
Capital Stock2.9 K3 K26.1 K
Very volatile
Capital Lease Obligations333.9 K318 K183.6 K
Very volatile

Oncternal Therapeutics Income Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Depreciation And Amortization43.8 M41.7 M7.1 M
Slightly volatile
Other Operating Expenses36.2 M42.5 M31.9 M
Pretty Stable
Research Development25.1 M29.8 M22.7 M
Pretty Stable
Total Operating Expenses12.1 M12.7 M28.2 M
Pretty Stable
Selling General Administrative9.5 M12.7 M9.9 M
Pretty Stable
Cost Of Revenue31.2 M29.8 M7.8 M
Slightly volatile
Discontinued Operations11.1 M12.5 M13.6 M
Slightly volatile
Reconciled Depreciation37.2 K41.4 K45.6 K
Slightly volatile
Net Interest Income2.4 M2.3 M491.7 K
Slightly volatile
Interest Income2.4 M2.3 M491.7 K
Slightly volatile
Non Recurring14.5 M16.3 M17.7 M
Slightly volatile
Selling And Marketing Expenses160 K180 K196 K
Slightly volatile

Oncternal Therapeutics Cash Flow Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
End Period Cash Flow6.4 M6.7 M33.2 M
Very volatile
Begin Period Cash Flow38.3 M37.1 M38.2 M
Pretty Stable
Total Cash From Financing Activities1 M1.1 M23.2 M
Very volatile
Stock Based Compensation7.9 M7.5 M3.8 M
Slightly volatile
Dividends Paid389 K409.5 K646.3 K
Slightly volatile
Issuance Of Capital Stock3.1 M3.2 M30 M
Very volatile

Financial Ratios

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Dividend Yield1.0E-41.0E-42.0E-4
Slightly volatile
Days Sales Outstanding28629497.432
Slightly volatile
Book Value Per Share10.7310.221828.0462
Very volatile
Capex To Depreciation0.03640.03830.3302
Pretty Stable
Payables Turnover27.2125.91725.3307
Slightly volatile
Cash Per Share11.0711.651434.311
Pretty Stable
Days Payables Outstanding13.3814.08334.7 K
Very volatile
Income Quality0.560.81470.8709
Slightly volatile
Intangibles To Total Assets0.00330.00350.0095
Slightly volatile
Current Ratio6.46.93717.3649
Pretty Stable
Tangible Book Value Per Share10.7310.221827.9291
Very volatile
Receivables Turnover1.181.24216.4164
Slightly volatile
Graham Number52.7955.573103
Pretty Stable
Debt To Equity0.00550.00620.0068
Slightly volatile
Capex Per Share9.0E-49.0E-40.2099
Slightly volatile
Interest Debt Per Share0.150.170.1875
Slightly volatile
Debt To Assets0.00360.00410.0045
Slightly volatile
Days Of Payables Outstanding13.3814.08334.7 K
Very volatile
Ebt Per Ebit1.330.94641.3801
Slightly volatile
Total Debt To Capitalization0.00550.00620.0067
Slightly volatile
Debt Equity Ratio0.00550.00620.0068
Slightly volatile
Quick Ratio6.46.93717.3737
Pretty Stable
Net Income Per E B T1.241.130.6564
Slightly volatile
Cash Ratio1.221.28845.4998
Very volatile
Days Of Sales Outstanding28629497.432
Slightly volatile
Free Cash Flow Operating Cash Flow Ratio1.191.151.0254
Slightly volatile
Fixed Asset Turnover2.893.042634.8012
Very volatile
Debt Ratio0.00360.00410.0045
Slightly volatile

Oncternal Therapeutics Valuation Data

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Market Cap34.4 M36.2 M1.1 B
Slightly volatile
Enterprise Value27.5 M28.9 M1 B
Slightly volatile

Oncternal Fundamental Market Drivers

Cash And Short Term Investments34.3 M

Oncternal Upcoming Events

14th of March 2024
Upcoming Quarterly Report
View
2nd of May 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
14th of March 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View

About Oncternal Therapeutics Financial Statements

Oncternal Therapeutics shareholders use historical fundamental indicators, such as revenue or net income, to determine how well the company is positioned to perform in the future. Although Oncternal Therapeutics investors may analyze each financial statement separately, they are all interrelated. The changes in Oncternal Therapeutics' assets and liabilities, for example, are also reflected in the revenues and expenses on on Oncternal Therapeutics' income statement. Understanding these patterns can help investors time the market effectively. Please read more on our fundamental analysis page.
Last ReportedProjected for Next Year
Current Deferred Revenue1.5 M1.4 M
Total Revenue785 K745.8 K
Cost Of Revenue29.8 M31.2 M
Stock Based Compensation To Revenue 9.55  10.03 
Sales General And Administrative To Revenue 16.24  17.05 
Research And Ddevelopement To Revenue 37.90  39.80 
Revenue Per Share 0.27  0.25 
Ebit Per Revenue(53.14)(50.48)

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.
Explore Investing Ideas  

Additional Tools for Oncternal Stock Analysis

When running Oncternal Therapeutics' price analysis, check to measure Oncternal Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Oncternal Therapeutics is operating at the current time. Most of Oncternal Therapeutics' value examination focuses on studying past and present price action to predict the probability of Oncternal Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Oncternal Therapeutics' price. Additionally, you may evaluate how the addition of Oncternal Therapeutics to your portfolios can decrease your overall portfolio volatility.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2024 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY